Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs

Bookmark and Share
Published: 1 Jun 2015
Views: 1648
Rating:
Save
Dr Richard Schilsky - University of Chicago, Chicago, USA

Dr Schilsky presents, at a press conference at ASCO 2015, the Targeted Agent and Profiling Utilization Registry (TAPUR).

It is the first ASCO-led clinical trial, which will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect "real-world" data on clinical outcomes to help learn the best uses of these drugs outside of indications.